Trial · NCT06461988
Talquetamab & Lenalidomide as Post Stem Cell Transplant Maintenance in Multiple Myeloma
NCT06461988, Phase 2, Recruiting, Stanford University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Talquetamab & Lenalidomide as Post Stem Cell Transplant Maintenance in Multiple Myeloma. Trials, record NCT06461988. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06461988
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Talquetamab & Lenalidomide as Post Stem Cell Transplant Maintenance in Multiple Myeloma
- NCT number
- NCT06461988
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 20 participants, estimated
- Lead sponsor
- Stanford University
- Conditions
- Multiple Myeloma, Post Stem Cell Transplant
- Interventions
- Talquetamab, Talquetamab and Lenalidomide
- First posted
- 2024-06-17
- Last updated
- 2026-07-17
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Stringent Complete Response (sCR) + Complete Response (CR) Rate | 12 months after the start of talquetamab in each participant. | The primary outcome for this study, for the purposes of Clinical Trials.gov registration and results reporting, is the percentage of patients in complete response at 12 months. |
| Secondary | Minimal Residual Disease (MRD) negativity (10^-5) (ClonoSeqTM) | 2 years | The percentage (%) of participants with MRD negativity (10\^-5) (ClonoSeqTM) at 12 months after starting talquetamab. |
| Secondary | Progression free survival (PFS) and overall survival (OS) | 4 years | Percentage (%) of participants with PFS and OS up to 3 years after starting talquetamab. |
| Secondary | Cytokine Release Syndrome (CRS), Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), and hematologic and non-hematologic toxicities per NCI CTCAE v5 criteria | 1 year and 1 months post first patient treatment start | Number of participants who experience a significant toxicity of interest (STI) in the first 3 months. |
| Secondary | Quality of life - PROMIS® (Patient-Reported Outcomes Measurement Information System and Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE®) | 2 years | PROMIS and PRO-CTCAE will be assessed monthly during study treatment and at end of treatment. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06461988
GET https://conductscience.org/api/trials/v1/NCT06461988/registered